Braveheart Bio, Inc. (BRVE)

NASDAQ: BRVE · Real-Time Price · USD

23.00

-0.61 (-2.58%)

Sep 23, 2026, 10:54 AM EDT - Market open

Braveheart Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025
Selling, General & Admin	11.88	3.02
Research & Development	23.53	1.49
Operating Expenses	35.4	4.51
Operating Income	-35.4	-4.51
Interest & Investment Income	2.36	0.7
Other Non Operating Income (Expenses)	0	0
EBT Excluding Unusual Items	-33.04	-3.81
Pretax Income	-94.84	-66.05
Net Income	-94.84	-66.05
Net Income to Common	-98.46	-66.05
Net Income Growth	-	-
Shares Outstanding (Basic)	7	4
Shares Outstanding (Diluted)	7	4
Shares Change	-	-
EPS (Basic)	-14.68	-17.20
EPS (Diluted)	-14.68	-17.20
EPS Growth	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025
EBIT	-35.4	-4.51

SEC Filings: 10-K · 10-Q